Experiment: 5JXV

SOLID-STATE NMR

NMR Experiment
Experiment	Type	Sample Contents	Solvent	Ionic Strength	pH	Pressure	Temperature (K)	Spectrometer
1	(H)NCAH	12.5 mM sodium phosphate, 45 % methyl-2,4-pentane diol, 22.5 % isopropyl alcohol, 800 mg/mL [U-99% 13C; U-99% 15N] B1 domain of Immunoglobulin G-Binding protein G	H20/MPD/IPA	12.5 mM	5.6	variable atm	283	Bruker AVANCE III 1000
11	(H)N(CO)CAH	12.5 mM sodium phosphate, 45 % methyl-2,4-pentane diol, 22.5 % isopropyl alcohol, 800 mg/mL [U-99% 13C; U-99% 15N] B1 domain of Immunoglobulin G-Binding protein G	H20/MPD/IPA	12.5 mM	5.6	variable atm	283	Bruker AVANCE III 1000
12	(H)COCAH	12.5 mM sodium phosphate, 45 % methyl-2,4-pentane diol, 22.5 % isopropyl alcohol, 800 mg/mL [U-99% 13C; U-99% 15N] B1 domain of Immunoglobulin G-Binding protein G	H20/MPD/IPA	12.5 mM	5.6	variable atm	283	Bruker AVANCE III 1000
13	(H)CO(N)CAH	12.5 mM sodium phosphate, 45 % methyl-2,4-pentane diol, 22.5 % isopropyl alcohol, 800 mg/mL [U-99% 13C; U-99% 15N] B1 domain of Immunoglobulin G-Binding protein G	H20/MPD/IPA	12.5 mM	5.6	variable atm	283	Bruker AVANCE III 1000
2	(H)CANH	12.5 mM sodium phosphate, 45 % methyl-2,4-pentane diol, 22.5 % isopropyl alcohol, 800 mg/mL [U-99% 13C; U-99% 15N] B1 domain of Immunoglobulin G-Binding protein G	H20/MPD/IPA	12.5 mM	5.6	variable atm	283	Bruker AVANCE III 1000
3	(H)(CO)CA(CO)NH	12.5 mM sodium phosphate, 45 % methyl-2,4-pentane diol, 22.5 % isopropyl alcohol, 800 mg/mL [U-99% 13C; U-99% 15N] B1 domain of Immunoglobulin G-Binding protein G	H20/MPD/IPA	12.5 mM	5.6	variable atm	283	Bruker AVANCE III 1000
4	(H)(CA)CB(CA)NH	12.5 mM sodium phosphate, 45 % methyl-2,4-pentane diol, 22.5 % isopropyl alcohol, 800 mg/mL [U-99% 13C; U-99% 15N] B1 domain of Immunoglobulin G-Binding protein G	H20/MPD/IPA	12.5 mM	5.6	variable atm	283	Bruker AVANCE III 1000
5	(H)N(CA)(CO)NH	12.5 mM sodium phosphate, 45 % methyl-2,4-pentane diol, 22.5 % isopropyl alcohol, 800 mg/mL [U-99% 13C; U-99% 15N] B1 domain of Immunoglobulin G-Binding protein G	H20/MPD/IPA	12.5 mM	5.6	variable atm	283	Bruker AVANCE III 1000
6	(H)N(CO)(CA)NH	12.5 mM sodium phosphate, 45 % methyl-2,4-pentane diol, 22.5 % isopropyl alcohol, 800 mg/mL [U-99% 13C; U-99% 15N] B1 domain of Immunoglobulin G-Binding protein G	H20/MPD/IPA	12.5 mM	5.6	variable atm	283	Bruker AVANCE III 1000
7	(H)CCH-TOCSY	12.5 mM sodium phosphate, 45 % methyl-2,4-pentane diol, 22.5 % isopropyl alcohol, 800 mg/mL [U-99% 13C; U-99% 15N] B1 domain of Immunoglobulin G-Binding protein G	H20/MPD/IPA	12.5 mM	5.6	variable atm	283	Bruker AVANCE III 1000
8	(H)NHH-RFDR	12.5 mM sodium phosphate, 45 % methyl-2,4-pentane diol, 22.5 % isopropyl alcohol, 800 mg/mL [U-99% 13C; U-99% 15N] B1 domain of Immunoglobulin G-Binding protein G	H20/MPD/IPA	12.5 mM	5.6	variable atm	283	Bruker AVANCE III 1000
9	(H)CHH-RFDR	12.5 mM sodium phosphate, 45 % methyl-2,4-pentane diol, 22.5 % isopropyl alcohol, 800 mg/mL [U-99% 13C; U-99% 15N] B1 domain of Immunoglobulin G-Binding protein G	H20/MPD/IPA	12.5 mM	5.6	variable atm	283	Bruker AVANCE III 1000
10	H(H)CH-RFDR-aromatic13C	12.5 mM sodium phosphate, 45 % methyl-2,4-pentane diol, 22.5 % isopropyl alcohol, 800 mg/mL [U-99% 13C; U-99% 15N] B1 domain of Immunoglobulin G-Binding protein G	H20/MPD/IPA	12.5 mM	5.6	variable atm	283	Bruker AVANCE III 1000

NMR Spectrometer Information
Spectrometer	Manufacturer	Model	Field Strength
1	Bruker	AVANCE III	1000

NMR Refinement
Method	Details	Software
torsion angle dynamics		CANDID

NMR Ensemble Information
Conformer Selection Criteria	target function
Conformers Calculated Total Number	80
Conformers Submitted Total Number	20
Representative Model	1 (target function)

Computation: NMR Software
#	Classification	Version	Software Name	Author
1	structure calculation	CANDID	2.6.0	Herrmann, Guntert and Wuthrich
3	chemical shift assignment	CARA		Keller and Wuthrich
5	chemical shift assignment	Sparky		Goddard
6	collection	TopSpin		Bruker Biospin
7	structure calculation	TALOS		Cornilescu, Delaglio and Bax
8	processing	NMRPipe		Delaglio, Grzesiek, Vuister, Zhu, Pfeifer and Bax

RCSB PDB Core Operations are funded by the National Science Foundation (DBI-1832184), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM133198.